4-(1-三苯甲基-1H-咪唑)-丁酸 | 102676-84-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 中文名称: 4-(1-三苯甲基-1H-咪唑)-丁酸
• 英文名称: 4-(1-trityl-1H-imidazol-4-yl)butyric acid
• 英文别名: 4-(1-Trityl-1H-imidazol-4-YL)-butyric acid；4-(1-tritylimidazol-4-yl)butanoic acid
• CAS: 102676-84-6
• 化学式: C₂₆H₂₄N₂O₂
• 分子量: 396.489
• InChiKey: IHSMTAHISORELK-UHFFFAOYSA-N

物化性质

• 沸点：
  574.2±45.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(1-三苯甲基-1H-咪唑)-丁酸 在 potassium carbonate 、 lithium diisopropyl amide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 2-Benzyl-4-(1-trityl-1H-imidazol-4-yl)-butyric acid methyl ester
  参考文献：
  名称：

  A new type of carboxypeptidase a inhibitors designed using an imidazole as a zinc coordinating ligand

  摘要：

  2-(4-Imidazoyl)hydrocinnamic acid (1) and its congeners (2-4) having different length of alkyl chain spacers between the imidazole ring and the a-carbon to the carboxylate of 1 have been designed, synthesized and evaluated as inhibitors for carboxypeptidase A to show that they are competitive inhibitors for the enzyme. Inhibitor 1 was most potent having the K-i value of 0.8 mu M. The present study demonstrates that imidazole ring is an effective zinc coordinating ligand that can be useful for the design of inhibitors for zinc proteases. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00134-x
• 作为产物：
  描述：

  1-三苯甲基咪唑-4-甲醛 在 palladium on activated charcoal sodium hydroxide 、 硫酸 、 氢气 、 sodium hydride 、 二甲基亚砜 作用下， 反应 25.0h， 生成 4-(1-三苯甲基-1H-咪唑)-丁酸
  参考文献：
  名称：

  A new type of carboxypeptidase a inhibitors designed using an imidazole as a zinc coordinating ligand

  摘要：

  2-(4-Imidazoyl)hydrocinnamic acid (1) and its congeners (2-4) having different length of alkyl chain spacers between the imidazole ring and the a-carbon to the carboxylate of 1 have been designed, synthesized and evaluated as inhibitors for carboxypeptidase A to show that they are competitive inhibitors for the enzyme. Inhibitor 1 was most potent having the K-i value of 0.8 mu M. The present study demonstrates that imidazole ring is an effective zinc coordinating ligand that can be useful for the design of inhibitors for zinc proteases. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00134-x

文献信息

• <i>N</i>^α-Imidazolylalkyl and Pyridylalkyl Derivatives of Histaprodifen:  Synthesis and in Vitro Evaluation of Highly Potent Histamine H₁-Receptor Agonists
  作者：Sonja Menghin、Heinz H. Pertz、Kai Kramer、Roland Seifert、Walter Schunack、Sigurd Elz

  DOI：10.1021/jm0309147

  日期：2003.12.1

  N(alpha)()-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen (6, 2-[2-(3,3-diphenylpropyl)imidazol-4-yl]ethanamine) was synthesized and evaluated as histamine H(1)-receptor agonists. The title compounds displayed partial agonism at contractile H(1)-receptors of guinea pig ileum and were at least equipotent with histamine. Agonist effects of the new derivatives were susceptible to blockade by the

  合成了一系列新的组胺苯丙胺的N（α）（）-咪唑基烷基和吡啶基烷基衍生物（6，2- [2-（3,3-二苯丙基）咪唑--4-基]乙胺）并评估为组胺H（1） -受体激动剂。标题化合物在豚鼠回肠的收缩性H（1）受体上表现出部分激动作用，并且至少与组胺等价。新衍生物的激动剂作用易于受到H（1）-受体拮抗剂美吡拉敏（2-100 nM）的阻滞。在咪唑系列中，suprahistaprodifen（51，[2- [2-（3,3-二苯丙基）-1H-咪唑-4-基]乙基]-[2-（1H-咪唑-4-基）乙基]酰胺，N（α）-2-[（（1H-咪唑-4-基）乙基]组己二酚）显示出有史以来最高的H（1）-受体激动剂效能（pEC（50）8.26，功效E（max） 96％）。烷基间隔物从乙基到丁基的延伸将活性从3630％（乙基，51）降低到163％（丁基，53）组胺效力。末端咪唑核交换成吡啶环产生具有相当高效力的化合物。当烷
• [EN] ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT COMPRENANT DES PEPTIDOMIMÉTIQUES DE GLP1 ET LEURS UTILISATIONS
  申请人：REGENERON PHARMA

  公开号：WO2022056494A1

  公开（公告）日：2022-03-17

  Described herein are protein-drug conjugates and compositions thereof that are useful, for example, for targeting glucagon-like peptide 1 receptor (GLP1R). In certain embodiments, provided are peptidomimetic payloads and linker-payloads and methods of making same. More specifically, GLP1 peptidomimetics, antibody-drug conjugates, and compositions which comprise anti-GLP1R antibodies and GLP1 peptidomimetic payloads and methods of treating GLP1R-associated conditions are provided.

  本文描述了蛋白质-药物结合物及其组合物，例如，用于靶向胰高血糖素样肽1受体（GLP1R）。在某些实施例中，提供了肽类类似物荷载和连接器-荷载以及制备它们的方法。更具体地，提供了GLP1类似物、抗体-药物结合物和组合物，其中包括抗GLP1R抗体和GLP1类似物荷载，并提供了治疗GLP1R相关疾病的方法。
• Substituted imidazo[5-a]pyridine derviatives and other substituted
  申请人：Ciba-Geigy Corporation

  公开号：US05428160A1

  公开（公告）日：1995-06-27

  Disclosed are compounds of formula I ##STR1## wherein R.sub.1 represents hydrogen, lower alkyl, substituted lower alkyl, nitro, halogen, free, etherified or esterified hydroxy, free, etherified, oxidised etherified or esterified mercapto, unsubstituted, mono- or disubstituted amino, ammonio, free or functionally modified sulfo, free or functionally modified formyl, C.sub.2 -C.sub.20 -acyl, cyano, free or functionally modified carboxy; and R.sub.2 represents hydrogen, lower alkyl, substituted lower alkyl, halogen; free, etherified or esterified hydroxy; free, etherified, oxidised etherified or esterified mercapto; free or functionally modified carboxy, or acyl; the 7,8-dihydro derivatives thereof; and compounds of the formula I* ##STR2## wherein n denotes 0, 1, 2, 3, or 4, and R.sub.1 and R.sub.2 are as defined above under formula I and salts thereof; e.g. as aromatase inhibitors; pharmaceutical compositions containing these compounds; the use of these compounds for the treatment of conditions responsive to e.g. aromatase inhibition in mammals; processes and intermediates for preparing these compounds.

  本发明涉及一种式子I的化合物：##STR1## 其中R.sub.1代表氢，低烷基，取代的低烷基，硝基，卤素，自由的，醚化或酯化的羟基，自由的，醚化，氧化醚化或酯化的巯基，未取代的，单取代或双取代的氨基，铵离子，自由的或功能修饰的磺酸基，自由的或功能修饰的甲酰基，C.sub.2-C.sub.20-酰基，氰基，自由的或功能修饰的羧基；R.sub.2代表氢，低烷基，取代的低烷基，卤素；自由的，醚化或酯化的羟基；自由的，醚化，氧化醚化或酯化的巯基；自由或功能修饰的羧基或酰基；其7,8-二氢衍生物；以及式I*的化合物：##STR2## 其中n表示0、1、2、3或4，而R.sub.1和R.sub.2如上述式I中所定义，并且它们的盐；例如作为芳香化酶抑制剂；含有这些化合物的制药组合物；这些化合物用于治疗响应于例如哺乳动物中的芳香化酶抑制的情况的用途；制备这些化合物的过程和中间体。
• Substituted imidazo[1,5-A]pyridine derivatives and other substituted
  申请人：Ciba-Geigy Corporation

  公开号：US04728645A1

  公开（公告）日：1988-03-01

  Disclosed are compounds of formula I ##STR1## wherein R.sub.1 represents hydrogen, lower alkyl, substituted lower alkyl, nitro, halogen, free, etherified or esterified hydroxy, free, etherified, oxidized etherified or esterified mercapto, unsubstituted, mono- or disubstituted amino, ammonio, free or functionally modified sulfo, free or functionally modified formyl, C.sub.2 -C.sub.20 -acyl, cyano, free or functionally modified carboxy; and R.sub.2 represents hydrogen, lower alkyl, substituted lower alkyl, halogen; free, etherified or esterified hydroxy; free, etherified, oxidized etherified or esterified mercapto; free or functionally modified carboxy, or acyl; the 7,8-dihydro derivatives thereof; and compounds of the formula I* ##STR2## wherein n denotes 0, 1, 2, 3 or 4, and R.sub.1 and R.sub.2 are as defined above under formula I and salts thereof; e.g. as aromatase inhibitors; pharmaceutical compositions containing these compounds; the use of these compounds for the treatment of conditions responsive to e.g. aromatase inhibition in mammals; processes and intermediates for preparing these compounds.

  本发明揭示了式I的化合物：##STR1## 其中R.sub.1代表氢、低碳基、取代的低碳基、硝基、卤素、自由、醚化或酯化的羟基、自由、醚化、氧化醚化或酯化的巯基、未取代的、单取代或双取代的氨基、铵离子、自由或功能修饰的磺酸基、自由或功能修饰的甲酰基、C.sub.2-C.sub.20酰基、氰基、自由或功能修饰的羧基；R.sub.2代表氢、低碳基、取代的低碳基、卤素；自由、醚化或酯化的羟基；自由、醚化、氧化醚化或酯化的巯基；自由或功能修饰的羧基或酰基。其7,8-二氢衍生物；以及式I*的化合物：##STR2## 其中n表示0、1、2、3或4，R.sub.1和R.sub.2如上所述，以及其盐；例如作为芳香化酶抑制剂；含有这些化合物的制药组合物；使用这些化合物治疗对哺乳动物的芳香化酶抑制等反应性疾病的方法；制备这些化合物的过程和中间体。
• Substituierte bicyclische Verbindungen
  申请人：CIBA-GEIGY AG

  公开号：EP0165904B1

  公开（公告）日：1991-04-10